The global advanced therapy medicinal products CDMO market size is expected to be worth around US$ 20.9 billion by 2030, according to a new report by Vision Research Reports.
The global advanced therapy medicinal products CDMO market size is expected to be worth around US$ 20.9 billion by 2030, according to a new report by Vision Research Reports.
The global advanced therapy medicinal products CDMO market size was valued at US$ 7.29 billion in 2020 and is anticipated to grow at a CAGR of 13.0% during forecast period 2021 to 2030.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39014
Growth Factors
The growing demand for advanced therapy is the key factor fueling the market growth. The growth is attributed to the increasing prevalence of rare and life-threatening diseases, such as metabolic and optical diseases, and rising investment in R&D of advanced therapy medicinal product. Besides, ATMPs such as mesenchymal stem cells (MSCs) are a new treatment effective against the COVID-19 virus.
The growth of the market is credited to the increasing clinical trials of ATMP and the rising awareness and belief among researchers regarding the benefits of advanced therapy. The COVID-19 pandemic has significantly disrupted the cell and gene therapy industry due to the complexity in the manufacturing process.
Report Coverage
|
Report Scope |
Details |
|
Market Size |
US$ 20.9 billion by 2030 |
|
Growth Rate |
CAGR of 13.0% From 2021 to 2030 |
|
Base Year |
2021 |
|
Forecast Period |
2021 to 2030 |
|
Segments Covered |
Product, Phase, Indication |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Companies Mentioned |
Celonic; Bio Elpida; CGT Catapult; Rentschler Biopharma SE; AGC Biologics; Catalent; Lonza; WuXi Advanced Therapies; BlueReg; Minaris Regenerative Medicine; Patheon |
By Product Analysis
The gene therapy accounted for the largest revenue share of over 51.0% in 2020. The rapid growth of the segment is attributed to the advancements in therapy as the treatment can alter and improve the genetics or specifically modify the targeted therapeutic treatment.
In the last few years, gene therapy has observed lucrative growth due to the efficiency in invading cells and initiating the genetic materials. The most common method used in gene therapy is recombinant DNA technology.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/39014
By Indication Analysis
Oncology accounted for the largest revenue share of over 46.0% in 2020. The growth of the segment is attributed to the increasing prevalence of cancer and chronic diseases owing to the rising geriatric population. Oncology is a branch of medicines, which diagnoses and treats cancer.
According to the WHO, cancer is the second-largest leading cause of death globally and nearly 10 million people died due to cancer in 2020. Most of the cancer cases have been found in undeveloped nations and it mainly affects the low- or middle-income countries due to the lack of a proper medical system.
By Phase Analysis
Phase III accounted for the largest revenue share of over 51.0% in 2020. The growth of the segment is owing to the fact that phase III trials involve a large number of patients, and this phase is also the most extensive study period as it includes a comparison of the efficiency and safety of the new drug.
Phase I held the second-largest revenue share in 2020 owing to the growing R&D activities. With the advent of the Covid-19 pandemic and the use of ATMPs in the treatment of infectious diseases, the segment is expected to witness lucrative growth over the next 2-3 years.
By Regional Analysis
North America held the largest revenue share of over 45.0% in 2020 owing to the growing awareness regarding advanced therapy and rising outsourcing activities.
The region has a favorable regulatory environment as the FDA has approved a few gene therapy products for sale in the U.S. such as ALLOCORD and ABECMA. According to the reports by American Biopharmaceutical Companies.
Related Reports
- Small Molecule innovator CDMO Market Report 2022-2030 - https://www.visionresearchreports.com/small-molecule-innovator-cdmo-market/39117
- Investigational New Drug CDMO Market Report 2022-2030 - https://www.visionresearchreports.com/investigational-new-drug-cdmo-market/38506
- Active Pharmaceutical Ingredients CDMO Market Report 2022-2030 - https://www.visionresearchreports.com/active-pharmaceutical-ingredients-cdmo-market/38335
Key Players
- Celonic
- Bio Elpida
- CGT Catapult
- Rentschler Biopharma SE
- AGC Biologics
- Catalent
- Lonza
- WuXi Advanced Therapies
- BlueReg
- Minaris Regenerative Medicine
- Patheon
Market Segmentation
- By Product
- Gene Therapy
- Cell Therapy
- Tissue Engineered
- Others (Combined ATMPs, for example biodegradable matric or scaffold)
- By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
- By Indication
- Oncology
- Cardiology
- Central Nervous System
- Musculoskeletal
- Infectious Disease
- Dermatology
- Endocrine, Metabolic, Genetic
- Immunology & Inflammation
- Ophthalmology
- Haematology
- Gastroenterology
- Others
- Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/39014
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/